Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 326517
                    [Title] => FDA grants priority review to new drug for acute STEMI
                    [Summary] => Sanofi-aventis and Bristol-Myers Squibb Co. announced recently that the US Food and Drug Administration (FDA) has accepted for review a supplemental new drug application for the antiplatelet agent clopidogrel bisulfate for the treatment of patients with acute ST-segment elevation myocardial infarction (STEMI).


STEMI is a heart attack in which an artery is generally blocked completely for sufficient time to cause heart muscle damage. This blockage is caused by clot formation in the arteries, which is also known as atherothrombosis.  


                    [DatePublished] => 2006-03-16 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

EUROPEAN MEDICINES EVALUATION AGENCY

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 326517
                    [Title] => FDA grants priority review to new drug for acute STEMI
                    [Summary] => Sanofi-aventis and Bristol-Myers Squibb Co. announced recently that the US Food and Drug Administration (FDA) has accepted for review a supplemental new drug application for the antiplatelet agent clopidogrel bisulfate for the treatment of patients with acute ST-segment elevation myocardial infarction (STEMI).


STEMI is a heart attack in which an artery is generally blocked completely for sufficient time to cause heart muscle damage. This blockage is caused by clot formation in the arteries, which is also known as atherothrombosis.  


                    [DatePublished] => 2006-03-16 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

FDA grants priority review to new drug for acute STEMI

March 16, 2006 - 12:00am

Sanofi-aventis and Bristol-Myers Squibb Co. announced recently that the US Food and Drug Administration (FDA) has accepted for review a supplemental new drug application for the antiplatelet agent clopidogrel bisulfate...

Science and Environment